CUTISS co-founder and CEO Daniela Marino shares insights with In Vivo about the future of regenerative medicine and the ongoing development of denovoSkin, a next-generation human skin graft technology.
What was once a tissue engineering project at the University of Zurich later became a clinical-stage life sciences company after...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
From solving delivery challenges for Moderna's COVID-19 vaccine to pioneering the next generation of programmable medicines, the 2025 Rising Leader provides mid-career reflections.
The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.
A 25-year-old's “naive optimism” becomes the driving force behind one of biopharma's most ambitious AI ventures.
The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.
Investors and healthcare philanthropists have launched a new women’s health fund – aiming to be the largest of its kind – with an ambitious goal to not just finance innovation, but to build a sustainable market around it.
2026 is positioned as a breakout year for the psychedelic therapeutics sector, with multiple players expected to deliver defining Phase III results – creating momentum across the industry.
The recall of various Respironics sleep and respiratory care devices in 2021 plunged Philips into static growth and market share loss. Careful remediation is the group’s top priority, but S&RC head Dan Leonard is determined that the manner of its achievement will be the envy of the industry.
